SMITHFIELD – Biotechnology firm Rubius Therapeutics Inc. was added to the Nasdaq biotechnology index on Dec. 24.
The company, based in Cambridge, Mass., but building a facility in Smithfield, announced the development in a news release.
A Simplified Approach to Designing and Implementing Internal Control in the Hospitality Industry
In my previous article, Internal Controls & Audits: Keys to a Resilient Hospitality Business, I…
Learn More
Rubius manufactures allogeneic cellular therapies called Red Cell Therapeutics, which have the potential to treat several different kinds of diseases, the company said.
The company recently secured a $75 million loan from Solar Capital Partners to advance its product line: red blood cells in medicines that can replace enzymes in patients with cancer and autoimmune diseases.
The 135,000-square-foot Smithfield property that Rubius bought in July was a former Alexion Pharmaceuticals facility.
“We are ensuring that we will have state-of-the-art manufacturing capabilities in place,” said CEO Dr. Pablo Cagnoni at that time.
The new location should be operational by 2020, Rubius said.
Susan Shalhoub is a PBN contributing writer.
